About Us


We operate our plants in accordance with cGMP and/or other applicable requirements. We currently operate four US FDA approved manufacturing facilities in North America and two US FDA approved manufacturing facilities in India.

We believe our large scale capacity manufacturing sites in India provide us with cost advantages in terms of wages and raw materials prices as compared to many of our global competitors, as well as economies of scale. In addition, by virtue of our integrated operations, we believe that we enjoy competitive advantages in the form of cost efficiencies by producing across the value chain, thereby reducing our dependence on third parties for supply of starting materials and helps to insulate us from significant volatility in raw materials prices. The APIs from our manufacturing facility are used in the Solid Dosage Formulations business. Such integration between our Solid Dosage Formulations and APIs business lines allows us to continuously improve our cost of production.

Montreal, Québec, Canada

US FDA, Health Canada approved facility for Sterile Injectables, Ophthalmic and Non-Sterile Semisolids.

Maryland, USA

US FDA and DEA approved facility for Generics

Washington, USA

US FDA, MHRA, Health Canada, PMDA Japan approved facility for Sterile Injectables, US FDA and Health Canada approved facility for Allergy Therapy products

Karnataka, India

USFDA, PMDA Japan, ANVISA Brazil, TGA Australia, KFDA Korean and COFEPRIS Mexico approved facility for Active Pharmaceutical Ingredients

Uttarakhand, India

USFDA, UKMHRA, PMDA Japan and MCC South Africa approved facility for Generics


We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.